Jump to Topics

Alzheimer’s detection gets easier with a new blood test

Alzheimer’s detection gets easier with a new blood test

Researchers have discovered a new method to determine tau protein in the blood, potentially aiding in the detection of Alzheimer’s disease
Representational Image: Shutterstock

Neuroscientists from the University of Pittsburgh, USA, have developed a blood test to detect tau protein build-up in the brain commonly seen in Alzheimer’s.  This test eliminates the need for a brain scan or cerebrospinal fluid (CSF) extraction. The study was published in Brain. 

Diagnosis of Alzheimer’s calls for the assessment of the ATN framework: accumulation of amyloid-beta protein (A), tau-tangle formation (T), and loss of neurons due to progressive neurodegeneration (N). Currently, a combination of brain imaging, laboratory testing and CSF extraction are required to assess for Alzheimer’s. 

“At present, diagnosing Alzheimer’s disease requires neuroimaging that is expensive and takes a long time to schedule,” Thomas Karikari, assistant professor at the University of Pittsburgh, said in a statement.  A blood test can detect the amyloid beta and tau specific to Alzheimer’s. However, assessing nerve cell damage involves CSF extraction, a painful procedure.  

Karikari’s team developed an antibody that specifically binds to brain-derived tau (BD-tau) and is detectable in a blood sample.  “A blood test is cheaper, safer, and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trial and disease monitoring,” says Karikari. 

The researchers analysed the blood samples of 600 participants in different stages of Alzheimer’s as well as healthy individuals to validate the results of their method.  They then compared the BD-tau value obtained from their method with those obtained through conventional CSF extraction and found the results matched. The new blood test could help in differentiating Alzheimer’s from other neurodegenerative conditions, their statement said.  

“The development of simple tools detecting the signs of Alzheimer’s in the blood without compromising quality is an important step toward improved accessibility,” Karikari said. 

Karikari’s team plans to conduct the validation test on a large-scale population encompassing different racial and ethnic backgrounds.

“While the exact costs are difficult to estimate, it is certain that they will be much lower than the cost of an MRI scan or a spinal tap. If approved [by the FDA] the tests can become available in as early as 2 years,” says Karikari to Happiest Health.

Share Your Experience/Comments

Leave a Reply

Your email address will not be published. Required fields are marked *



Insufficient consumption of heart-healthy foods can affect cardiovascular health. Experts discuss beneficial dietary choices
Some couples consciously decide not to have children despite familial and social expectations, wanting to make the best of their relationship. Children should be had for their own sake, says psychotherapist Tasneem Nakhoda
Physical activity improves the quality as well as duration of sleep. But exercising too close to bedtime is not advisable




Opt-in To Our Daily Newsletter

* Please check your Spam folder for the Opt-in confirmation mail

Opt-in To Our
Daily Newsletter

We use cookies to customize your user experience, view our policy here

Your feedback has been submitted successfully.

The Happiest Health team will reach out to you at the earliest